Treatment of pure ocular myasthenia

A proposal from Japan MG registry 2012

Research output: Contribution to journalArticle

Abstract

Autoimmune myasthenia gravis (MG), affecting both ocular and generalized muscles, results in various symptoms. Ocular myasthenia (OM) is a form of MG that is clinically restricted to extrinsic ocular muscles. Clinical signs of OM can be highly variable, ranging from mild unilateral ptosis to complete opthalmoplegia. There is no clear evidence supporting corticosteroid use for OM. We studied 123 patients whose symptoms were limited to ocular muscles with duration of illness ≥ 2 years. We classified them into two groups: 36 patients with ptosis alone (the ptosis group) and 87 with diplopia with or without ptosis (the diplopia group). Prednisolone (PSL) and immunosuppressants were less frequently used in the ptosis group. There were no significant differences in the post-treatment condition and quality-of-life (QOL) impairment between the two groups. Forty-seven (38%) patients who failed to gain minimal manifestation or better status with PSL ≤ 5 mg/day (the unfavorable condition) showed severe QOL impairment. Ocular-QMG score was a factor associated with the unfavorable condition. A treatment strategy, discriminated by ptosis or diplopia, is necessary to improve the ocular symptoms and QOL in OM patients with the unfavorable condition.

Original languageEnglish
Pages (from-to)1303-1305
Number of pages3
JournalClinical Neurology
Volume53
Issue number11
DOIs
Publication statusPublished - 2013

Fingerprint

Myasthenia Gravis
Registries
Japan
Diplopia
Therapeutics
Quality of Life
Prednisolone
Muscles
Immunosuppressive Agents
Adrenal Cortex Hormones

Keywords

  • Ocular myasthenia, diplopia, ptosis, unfavorable condition, qol

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Treatment of pure ocular myasthenia : A proposal from Japan MG registry 2012. / Suzuki, Shigeaki.

In: Clinical Neurology, Vol. 53, No. 11, 2013, p. 1303-1305.

Research output: Contribution to journalArticle

@article{c5792bccd3d9419ab50e577a20721231,
title = "Treatment of pure ocular myasthenia: A proposal from Japan MG registry 2012",
abstract = "Autoimmune myasthenia gravis (MG), affecting both ocular and generalized muscles, results in various symptoms. Ocular myasthenia (OM) is a form of MG that is clinically restricted to extrinsic ocular muscles. Clinical signs of OM can be highly variable, ranging from mild unilateral ptosis to complete opthalmoplegia. There is no clear evidence supporting corticosteroid use for OM. We studied 123 patients whose symptoms were limited to ocular muscles with duration of illness ≥ 2 years. We classified them into two groups: 36 patients with ptosis alone (the ptosis group) and 87 with diplopia with or without ptosis (the diplopia group). Prednisolone (PSL) and immunosuppressants were less frequently used in the ptosis group. There were no significant differences in the post-treatment condition and quality-of-life (QOL) impairment between the two groups. Forty-seven (38{\%}) patients who failed to gain minimal manifestation or better status with PSL ≤ 5 mg/day (the unfavorable condition) showed severe QOL impairment. Ocular-QMG score was a factor associated with the unfavorable condition. A treatment strategy, discriminated by ptosis or diplopia, is necessary to improve the ocular symptoms and QOL in OM patients with the unfavorable condition.",
keywords = "Ocular myasthenia, diplopia, ptosis, unfavorable condition, qol",
author = "Shigeaki Suzuki",
year = "2013",
doi = "10.5692/clinicalneurol.53.1303",
language = "English",
volume = "53",
pages = "1303--1305",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "11",

}

TY - JOUR

T1 - Treatment of pure ocular myasthenia

T2 - A proposal from Japan MG registry 2012

AU - Suzuki, Shigeaki

PY - 2013

Y1 - 2013

N2 - Autoimmune myasthenia gravis (MG), affecting both ocular and generalized muscles, results in various symptoms. Ocular myasthenia (OM) is a form of MG that is clinically restricted to extrinsic ocular muscles. Clinical signs of OM can be highly variable, ranging from mild unilateral ptosis to complete opthalmoplegia. There is no clear evidence supporting corticosteroid use for OM. We studied 123 patients whose symptoms were limited to ocular muscles with duration of illness ≥ 2 years. We classified them into two groups: 36 patients with ptosis alone (the ptosis group) and 87 with diplopia with or without ptosis (the diplopia group). Prednisolone (PSL) and immunosuppressants were less frequently used in the ptosis group. There were no significant differences in the post-treatment condition and quality-of-life (QOL) impairment between the two groups. Forty-seven (38%) patients who failed to gain minimal manifestation or better status with PSL ≤ 5 mg/day (the unfavorable condition) showed severe QOL impairment. Ocular-QMG score was a factor associated with the unfavorable condition. A treatment strategy, discriminated by ptosis or diplopia, is necessary to improve the ocular symptoms and QOL in OM patients with the unfavorable condition.

AB - Autoimmune myasthenia gravis (MG), affecting both ocular and generalized muscles, results in various symptoms. Ocular myasthenia (OM) is a form of MG that is clinically restricted to extrinsic ocular muscles. Clinical signs of OM can be highly variable, ranging from mild unilateral ptosis to complete opthalmoplegia. There is no clear evidence supporting corticosteroid use for OM. We studied 123 patients whose symptoms were limited to ocular muscles with duration of illness ≥ 2 years. We classified them into two groups: 36 patients with ptosis alone (the ptosis group) and 87 with diplopia with or without ptosis (the diplopia group). Prednisolone (PSL) and immunosuppressants were less frequently used in the ptosis group. There were no significant differences in the post-treatment condition and quality-of-life (QOL) impairment between the two groups. Forty-seven (38%) patients who failed to gain minimal manifestation or better status with PSL ≤ 5 mg/day (the unfavorable condition) showed severe QOL impairment. Ocular-QMG score was a factor associated with the unfavorable condition. A treatment strategy, discriminated by ptosis or diplopia, is necessary to improve the ocular symptoms and QOL in OM patients with the unfavorable condition.

KW - Ocular myasthenia, diplopia, ptosis, unfavorable condition, qol

UR - http://www.scopus.com/inward/record.url?scp=84891754271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891754271&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.53.1303

DO - 10.5692/clinicalneurol.53.1303

M3 - Article

VL - 53

SP - 1303

EP - 1305

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 11

ER -